Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $93.31, while Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B). Which is the better fit depends on your goals.
| IEF | RXRX | |
|---|---|---|
52-Week High | $97.99 | $6.79 |
52-Week Low | $93.11 | $2.84 |
Market Cap | — | $1.53B |
Sector | — | Health |
Enterprise Value | — | $946.50M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
